Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Company ParticipantsDarren Snellgrove - VP of Investor RelationsJohn Reed - EVP of Innovative Medicine and R and DJoaquin Duato - CEOJoseph Wolk - CFOJennifer Taubert - EVP and Worldwide Chairman of Innovative MedicineConference Call ParticipantsTerence Flynn - AnalystAlexandria Hammond - AnalystVamil Divan - AnalystJoanne Wuensch - AnalystChris Schott - AnalystShagun Singh - AnalystLarry Biegelsen - AnalystAsad Haider - Analyst ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Company ParticipantsDarren Snellgrove - VP of Investor RelationsJohn Reed - EVP of Innovative Medicine and R and DJoaquin Duato - CEOJoseph Wolk - CFOJennifer Taubert - EVP and Worldwide Chairman of Innovative MedicineConference Call ParticipantsTerence Flynn - AnalystAlexandria Hammond - AnalystVamil Divan - AnalystJoanne Wuensch - AnalystChris Schott - AnalystShagun Singh - AnalystLarry Biegelsen - AnalystAsad Haider - Analyst ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings call January 21, 2026 08:30 AM ET Speaker1Good morning and welcome to Johnson & Johnson's fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you experience technical difficulties during the conference, you may press star zero to reach the operator. I will now turn the con ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Research Scientist in LabCanva Stock ImageFor years, public debate around U.S. dependence on China has focused on semiconductors, consumer electronics, rare earth minerals and industrial manufacturing. Far less attention has been paid to a quieter—but arguably more consequential shift taking place in the life sciences and biotech industry.When you think about the major science hubs – Boston, San Francisco Bay Area and San Diego probably come to mind. But what about Shanghai, Suzhou, Beijing, Shenzhen and Gu ...

th January 21, 2026 Cautionary note on Forward-looking statements This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate ...

Futures have reversed modest overnight gains and are trading near session lows while small caps continue to outperform (for a record 12th day in a row) even as Japanese and global bond yields stabilize and the market awaits today's major catalysts including Trump's speech in Davos due within the hour after flight had to be changed due to mechanical issues, while the Supreme Court will consider whether Trump can fire the Fed’s Cook.Selling pressure initially eased after Trump struck a more conciliatory tone  ...

In a victory for thousands of women suing Johnson & Johnson over claims that the company’s baby powder and other talc products caused their ovarian cancer, a court-appointed special master recommended on Tuesday that they be allowed to present testimony at trial from experts who support that link.The recommendation from retired U.S. District Judge Freda Wolfson, in long-running litigation that includes more than 67,500 lawsuits in the federal court in New Jersey, allows the cases to move towards the first t ...

Group 1 - The fourth quarter earnings season is gaining momentum, with major financial institutions like Charles Schwab and regional banks such as Fifth Third set to report results, alongside Netflix and Intel, which are expected to be focal points of the earnings calendar [1][5] - An optimistic consensus is emerging, with 7% of S&P 500 companies having reported fourth quarter results as of January 16, and analysts projecting an 8.2% increase in earnings per share for the quarter, marking the potential for the 10th consecutive quarter of annual earnings growth for the index [2] - Analysts had initially anticipated an 8.3% increase in earnings per share heading into the reporting period, a decrease from the previous quarter's 13.6% growth rate, but expectations have been raised recently, particularly for technology companies that have been key drivers of earnings growth [3] Group 2 - The current earnings season is expected to test the improved stock market breadth observed at the beginning of 2026, with ongoing themes from 2025, such as artificial intelligence and economic policies, continuing to influence market dynamics [4] - This week's earnings releases will also include reports from notable companies such as United Airlines, 3M Company, D.R. Horton, Johnson & Johnson, GE Aerospace, Procter & Gamble, Abbott Laboratories, and Capital One [5]

智通财经APP获悉，有着美股市场"大蓝筹"称号的医疗科技兼医药保健巨头强生(JNJ.US)于周三美股盘 前公布2025年第四季度核心业绩数据以及2026年业绩展望。按调整后口径，这家医疗保健领军者在第四 季度实现整体季度盈利约60亿美元——意味着实现同比增长22%，即每股2.46美元，分析师们此前普遍 预计每股利润约为2.44美元。第四季度营收245.6亿美元也高于华尔街分析师们普遍预期的241.6亿美 元，意味着实现同比超预期增长9.1%。 强生Q4整体销售额以及利润均高于华尔街预期，受益于血癌疗法Darzalex的强劲销售、银屑病药物 Tremfya的稳健增长，以及其医疗器械业务的强大韧性。 其规模最大的创新药(Innovative Medicine)部门本季度销售额增长10%，至157.6亿美元，高于预期的 153.7亿美元。 该公司预计2026年按业务经营统计口径(operational)计算的销售额指引区间约为995亿美元至1005亿美 元，根据伦敦LSEG汇编的分析师预期数据，高于华尔街分析师们普遍预估的约989亿美元。 强生管理层预计2026年全年的调整之后每股收益区间为11.43美元至11.6 ...